http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
오늘 본 자료
Hidaka, M.,Ohashi, K.,Wijesundera, R. P.,Kumara, L. S. R.,Sugihara, S.,Momoshima, N.,Kubuki, S.,Sung, N. E. SciELO 2011 Cerâmica Vol.57 No.342
<▼1><P>HIZEN celadon glazes produced in 1630's to 1790's (Edo period, Japan) have been investigated by means of X-ray absorption spectra (XAS) near a Fe-K edge by using synchrotron radiation and a Mössbauer spectrum. The XAS suggest that the local structure around Fe2O3 fine powders is slightly different between the Izumiyama ceramics of mainly the Quartz-SiO2 and Ohkawachi ceramics of mainly the feldspar of (K,Na)Si3O8 (Sanidine), and that the glazes of the HIZEN celadons include the Fe2O3 fine powders in the glassy state, though the X-ray diffraction patterns of the glassy celadon glazes do not show any peaks of the Fe2O3 structure. The Mössbauer spectrum suggests that the celadon glaze of Seiji (m) includes only Fe3+ ions, but not Fe2+ ions. This indicates the existence of Fe2O3 in the celadon glaze. It is interpreted that the colored brightness of the HIZEN celadons is induced by the structural properties of the used raw celadon ceramics and the other transition-metal ions of Cr, Cu, Zn in the celadon glazes, but not by the chemical reaction from Fe2O3 to FeO under the deoxidizing thermal treatment at higher temperature in a kiln.</P></▼1><▼2><P>Esmaltes de celadon Hizen produzidos dos anos 1630 a 1790 (período Edo, Japão) foram investigados por meio de espectros de absorção de raios X (XAS) próximos da linha Fe-K usando radiação síncrotron e espectro Mossbaues. Os resultados de XAS sugerem que a estrutura local em pós finos de Fe2O3 é levemente diferente entre as cerâmicas Izumiyama principalmente o quartzo e cerâmicas Ohkawachi principalmente do feldspato (K,Na)Si3O8 (Sanidine), e que os esmaltes dos celadons Hizen incluem finos pós de Fe2O3 no estado vítreo, embora os difratogramas de raios X dos esmaltes celadon não mostrem picos da estrutura do Fe2O3. O espectro Mossbauer sugere que os esmaltes celadon de Seiji (m) incluem somente íons Fe3+, mas não Fe2+. Isto indica a existência de Fe2O3 no esmalte celadon. É feita a interpretação que o brilho nas cores dos celadons Hizen é induzido pelas propriedades estruturais das cerâmicas básicas de celadon e os outros metais de transição Cr, Cu, Zn nos esmaltes celadon, mas não pela reação química entre Fe2O3 para FeO sob tratamento térmico desoxidante em forno a altas temperaturas.</P></▼2>
Drug compound characterization by mass spectrometry imaging in cancer tissue
권호정,Johan Malm,김용효,Yutaka Sugihara,Bo Baldetorp,Charlotte Welinder,Ken-ichi Watanabe,Toshihide Nishimura,Gyo¨rgy Marko-Varga,Szilvia To¨ro¨k,Bala´zs Do¨me,´ kos Ve´gva´ri,Lena Gustavsson,Thomas E. Feh 대한약학회 2015 Archives of Pharmacal Research Vol.38 No.9
MALDI mass spectrometry imaging (MSI)provides a technology platform that allows the accuratevisualization of unlabeled small molecules within the twodimensionalspaces of tissue samples. MSI has proven to bea powerful tool-box concept in the development of newdrugs. MSI allows unlabeled drug compounds and drugmetabolites to be detected and identified and quantifiedaccording to their mass-to-charge ratios (m/z) at high resolutionin complex tissue environments. Such drug characterizationin situ, by both spatial and temporal behaviorswithin tissue compartments, provide new understandings ofthe dynamic processes impacting drug uptake and metabolismat the local sites targeted by therapy. Further, MSIin combination with histology and immunohistochemistry,provides the added value of defining the context of cellbiology present at the sites of drug localization thus providinginvaluable information relating to treatment efficacy. In this report we provide mass spectrometry imagingdata within various cancers such as malignant melanoma inpatients administered with vemurafenib, a protein kinaseinhibitor that is targeting BRAF mutated proteins and thathas shown significant efficacy in restraining disease progression. We also provide an overview of other examplesof the new generation of targeted drugs, and demonstratethe data on personalized medicine drugs localization withintumor compartments within in vivo models. In these cancermodels we provide detailed data on drug and target proteinco-localization of YCG185 and sunitinib. These drugs aretargeting VEGFR2 within the angiogenesis mechanism. Our ability to resolve drug uptake at targeted sites ofdirected therapy provides important opportunities forincreasing our understanding about the mode of action ofdrug activity within the environment of disease.